Compare Aurora Cannabis Inc (ACB) vs IQIYI Inc - ADR (IQ) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

iQIYI (IQ) trades at $1.33, up 3.1% in 24 hours, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q1 2026 revenue of $915.2M, missing expectations, but beat EPS estimates. Valuation ratios show low P/S and P/B, but negative profitability metrics persist. Recent news highlights AI platform growth and leadership changes, with analyst consensus leaning buy.

Outlook: Potential upside exists from AI initiatives and cost controls, but risks include revenue declines, regulatory pressures, and negative cash flow projections. Investors should weigh low valuation against profitability challenges and China market volatility.